Author： Galic Vijaya L Wright Jason D Lewin Sharyn N Herzog Thomas J
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.6, 2011-06, pp. : 813-821
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Paclitaxel poliglumex promising in heavily-pretreated ovarian cancer
Inpharma, Vol. 1, Iss. 1467, 2004-01 ,pp. :
Access to resources
Recommend
Paclitaxel poliglumex a stellar performer in NSCLC
Inpharma, Vol. 1, Iss. 1517, 2005-01 ,pp. :
Paclitaxel vs cyclophosphamide, + cisplatin, for ovarian cancer
Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. :
QOL better with carboplatin + paclitaxel for ovarian cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 498, 2006-01 ,pp. :
Paclitaxel plus cisplatin and lonidamine showed `good activity' in advanced ovarian cancer
Inpharma, Vol. 1, Iss. 1285, 2001-01 ,pp. :